Track market-moving stories before they get noisy

Oracle (NYSE: ORCL) will pay its next quarterly dividend on July 24, 2026, with shareholders set to receive $0.50 per share.

As a result, investors holding 100 ORCL shares will collect $50 from the upcoming payment before taxes.

The software and cloud computing giant declared the dividend with an ex-dividend date of July 10, 2026. 

The payout remains unchanged from the previous quarter, bringing Oracle’s annual dividend to $2 per share and yielding approximately 1.09% at its current share price.

 At the current payout rate, investors holding 100 shares would generate $200 in annual dividend income.

Oracle has maintained a relatively modest dividend yield throughout its expansion, reflecting management’s focus on reinvesting capital into growth initiatives rather than prioritizing larger cash distributions.

The dividend payment comes during a volatile period for Oracle stock. Shares closed at $184 on June 12, down roughly 15% from levels above $200 reached earlier in the week following the company’s latest earnings report.

ORCL stock dividend details. Source: Dividend.com Oracle fundamentals  While Oracle delivered strong fiscal 2026 results, investors focused on the scale of planned AI-related spending and the potential impact on margins, cash flow, and debt levels.

Oracle reported fiscal 2026 revenue of $67.4 billion, up 17% year over year, while cloud revenue surged 39% to $34 billion. Demand for Oracle Cloud Infrastructure continued to accelerate, helping the company build a record remaining performance obligation (RPO) backlog of $638 billion.

The backlog increased by approximately $85 billion from the previous quarter and provides significant visibility into future revenue growth. 

Much of the contracted business is tied to large multi-year cloud and artificial intelligence agreements that are expected to support Oracle’s expansion over the coming years.

Despite those strong fundamentals, concerns about rising debt levels, margin pressure, and elevated AI infrastructure spending weighed on investor sentiment and pushed the stock lower in the days following earnings.

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Nvidia (NVDA +0.15%) and Micron Technology (MU 1.02%) each have seen revenue soar amid this artificial intelligence (AI) boom. This is because these companies offer something that is crucial for the development and performance of this hot technology: compute power, and memory and storage.

Nvidia is the compute expert, designing the fastest graphics processing units (GPUs) around, while Micron offers the memory and storage necessary for AI tasks. Investors have recognized these companies' strengths and have rushed to get in on the stocks. As a result, Nvidia and Micron each have climbed more than 1,000% over the past five years.

Both of these companies are likely to win as this AI story continues to unfold. But if you could only invest in one today, which is the better AI growth buy? Let's find out.

Image source: Getty Images.

The case for Nvidia Nvidia is the leading designer of GPUs, the chips powering key AI tasks like the training and inference of AI models. Though rivals also offer compute, and in many cases are delivering revenue growth too, Nvidia remains a big step ahead. Companies may invest in a broad range of compute, but those who aim to win in AI generally rely at least partially on Nvidia's GPUs -- their high speed helps customers reach the finish line faster and may result in a lower total cost of ownership over time.

Today's Change

(

0.15

%) $

0.30

Current Price

$

205.18

But Nvidia doesn't rely on GPUs alone. The company offers a full portfolio of related products and services, and today it's in the process of entering another enormous market: the central processing unit (CPU) market. These are the chips that generally power all computers, and they are a key tool to fuel AI agents, the next area of AI growth. Nvidia is launching its first-ever stand-alone CPU this fall and is conquering the CPU for PC market with a new superchip. This may set it on track for leadership in this $200 billion market.

Nvidia also has designed products and services specifically for certain markets, from telecom to healthcare and robotics, which offers it a pretty significant revenue growth opportunity moving forward.

The case for Micron Micron, as mentioned, is an expert in memory and storage -- two critical elements for AI customers, particularly as the era of AI agents unfolds. AI agents go through a thought process and carry out steps, in many cases multiple steps, to solve a particular problem. For this, they clearly need compute power but also memory and storage.

Demand for these products has been so high that Micron recently reported records in revenue, gross margin, earnings per share, and free cash flow, and revenue from DRAM and NAND, two types of memory, increased in the triple digits.

"In the AI era, memory has become a strategic asset for our customers," the company said in the latest earnings update.

Today's Change

(

-1.02

%) $

-10.15

Current Price

$

985.72

Micron has noted increased adoption of AI agents in PCs and smartphones, a point that supports ongoing demand for the company's products.

The tech giant expects earnings records in the current quarter, the third fiscal quarter. Micron predicts free cash flow will "roughly double sequentially" in the period. And it forecasts third-quarter revenue of $33.5 billion, a record high for any quarter or year so far.

The biggest headwind for Micron at this point is supply -- due to supply constraints, it's unable to serve 100% of its customers' needs.

Which stock is the better buy? Though Nvidia and Micron both have climbed this year, Micron's advance is much steeper than that of Nvidia. It's soared more than 240%, while Nvidia has added 9% as of the June 11 market close.

Micron actually is cheaper than Nvidia: It trades for 16x forward earnings estimates, while Nvidia trades for 22x. But while Nvidia's valuation has fallen this year, Micron's has increased.

NVDA PE Ratio (Forward) data by YCharts

I think Micron is a great stock to own, but the run-up in its price and rising valuation suggest this player could be heading for a pullback at a certain point. Meanwhile, Nvidia, at today's valuation, offers investors a fantastic buying opportunity. And that's why, today, I think Nvidia is the better AI growth buy to add to a tech portfolio.

The semiconductor design business is booming.

*Stock prices used were the afternoon prices of June 11, 2026. The video was published on June 13, 2026.

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Broadcom. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

The generative artificial intelligence (AI) revolution is in full force, with agentic AI now catapulting AI-related stocks to new heights.

Still, those who remember the internet boom and bust know that many darlings of that boom didn't become long-term winners. Some even went bankrupt. However, those who eventually emerged as winners of that boom became some of the world's biggest companies, making up most of today's "Magnificent Seven."

Today, the multitrillion-dollar question is, who will be the winner of the AI revolution? Well, Berkshire Hathaway's (BRKA +0.76%) (BRKB +0.71%) Greg Abel just made a big bet that one of the Magnificent Seven internet-era winners will also win the AI races -- and Berkshire's investment itself could help make that bet a reality.

Today's Change

(

0.53

%) $

1.90

Current Price

$

359.67

Berkshire triples down on Google In the first quarter -- Abel's first with total control over Berkshire's investment decisions -- Berkshire more than tripled its investment in Google parent Alphabet (GOOG +0.45%) (GOOGL +0.53%).

In addition to tripling down on Alphabet stock last quarter, Berkshire subsequently said it would buy another $10 billion worth of the $80 billion equity raise that Alphabet recently announced on June 1. That would equate to another 28.6 million shares, increasing Berkshire's stake by another 50%, barring any additional Alphabet purchases made since March 31.

As of this writing, Berkshire's combined 86.7 million shares (that we know about) would amount to about a $30.9 billion stake at today's share price. That would make Alphabet Berkshire's fourth-largest public equity holding, behind only Apple, American Express, and Coca-Cola.

Alphabet has survived, now primed to thrive in AI Back when Berkshire first established its position in Alphabet, I wrote that the likely reason was a reacceleration in Search-related paid clicks, which occurred in the second quarter of 2025 and was subsequently reported in the third quarter, when Berkshire took its initial position.

Alphabet was the cheapest of the Magnificent Seven stocks at that point due to fears that generative AI could disrupt Google Search, Alphabet's main cash cow. However, after Alphabet innovated and introduced features such as AI Overviews and AI Mode within the Search bar, paid clicks reaccelerated. That appeared to prove that the Search business wasn't going away, thanks to Alphabet's innovation.

However, Alphabet's stock has roughly doubled over the past year, and its valuation has risen accordingly. No longer is Alphabet the typical value investment that investors have come to expect from Berkshire. Berkshire's investment in Alphabet at a high-20s price-to-earnings (P/E) ratio indicates a conviction not only in Alphabet's survival but also its long-term competitive advantage in generative AI.

Image source: Getty Images.

Alphabet's advantage over start-up rivals Today, three large language models are currently regarded as the most advanced: Gemini by Alphabet, ChatGPT by OpenAI, and Claude by Anthropic. It seems as though Berkshire now believes Alphabet will win the generative AI race.

Both OpenAI and Anthropic are still private and, as of the latest data, remain unprofitable -- although Anthropic is projected to turn an operating profit for the first time this quarter. Still, Alphabet's current profitability, with $160 billion in net income over the past 12 months, dwarfs both companies' financial resources by a lot.

Aside from having much more financial resources, Alphabet also has another big cost advantage: It builds its own data centers and designs its own chips, called Tensor Processing Units. This is in contrast to OpenAI and Anthropic, which have to rent capacity from other clouds at a margin, on top of those clouds generally running more expensive Nvidia graphics processing units (GPUs).

If Alphabet has competitive AI algorithms, its current cost advantages should allow it to serve tokens to customers at a lower cost while also enabling it to provide more capacity amid insatiable demand. This could be what Berkshire sees.

An $80 billion raise could extend the advantage Both Anthropic and OpenAI have been raising capital in private markets this year, and each has filed to go public, likely later in the year. AI token demand is booming, and each needs to buy computing resources to meet it.

But Alphabet pre-empting those IPOs by raising an additional $80 billion on top of its internal cash flow not only matches the upcoming raises for Anthropic and OpenAI but could also even extend its advantage by raising this amount first.

This is because memory and chips are currently in short supply, with large companies prepaying and committing to buy semiconductors and high-bandwidth memory over multiple years. If Alphabet can make larger commitments earlier, that could box out competitors or raise the price of compute for everyone else, including Anthropic and OpenAI, who have fewer financial resources.

At this critical juncture in the AI race, with the winners yet to be determined, this strategic move could make a big difference.

There were once many search engines, too Back in the early days of the internet, before Google emerged, there were many search engines. However, Google emerged as the dominant, near-monopoly on this incredibly profitable business. It appears that Greg Abel thinks Alphabet still has the core competency to pull off a repeat with generative AI -- a market that could be multiples larger than Search is today.

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study
Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion
No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management
Additional translational data showed rapid vector clearance, polyclonal vector integration, and no evidence of non-specific transduction
Proof-of-concept progress demonstrates leadership in next-generation cell therapies, with results presented in a late-breaking session at EHA 2026
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).

In the ongoing Phase 1 study, a single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion. At the higher dose level (DL2), LB2501 achieved a 100% objective response rate (ORR) (6/6) and an 83.3% complete response rate (CR) (5/6), with all responses ongoing at the time of data cutoff. LB2501 also showed a favorable safety profile, with no dose-limiting toxicities (DLTs), serious adverse events (SAEs), immune effector cell-associated neurotoxicity syndrome (ICANS), or deaths reported.

“In vivo CAR-T represents a compelling frontier in cell therapy, enabling the generation of CAR-T cells directly within the patient, with the potential to simplify treatment and expand access over time,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “LB2501 is our step toward realizing that vision and reflects further progress toward our goal of leading the future of cell therapy. Backed by the commercial and scientific foundation we have built with CARVYKTI, we are well-positioned to advance this next generation of CAR-T delivery. These early data, with deep responses from a single infusion across patients, give us confidence in the path ahead.”

LB2501 Demonstrates In Vivo CAR-T Generation and Early Clinical Activity

In an ongoing Phase 1 study, 12 patients with R/R B-NHL received LB2501 across two dose levels, DL1 (n=6) and DL2 (n=6). Patients had received a median of three prior lines of therapy, and 58.3% were refractory to their most recent treatment. The open-label, multi-center, dose-escalation study is evaluating safety, recommended Phase 2 dose, pharmacokinetics, and preliminary efficacy in adults with R/R B-NHL. The study was conducted without lymphodepletion.

At DL2, LB2501 achieved a 100% ORR (6/6) and an 83.3% CR rate (5/6), with responses observed across patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Across both dose levels, the ORR was 50.0% (6/12), and the CR rate was 41.7% (5/12). At the time of data cutoff, all responses at DL2 were ongoing.

LB2501 showed a favorable safety profile. No DLTs, SAEs, ICANS, or deaths were reported. Infusion-related reactions (IRR) and cytokine release syndrome (CRS) were the most common adverse events of special interest and were all Grade 1–2. Infusion-related reactions occurred in 75.0% (9/12) of patients overall, with a median onset of 1.4 hours after infusion and a median recovery time of 18.6 hours. CRS occurred in 66.7% (8/12) of patients overall, with a median onset at Day 11 and a median duration of 4.5 days. IRR and CRS were all Grade 1–2, no patients required glucocorticoids for CRS management. Four patients received tocilizumab.

Pharmacokinetic analyses showed dose-dependent in vivo CAR-T expansion in 100% (6/6) of patients at DL2 and 83% (5/6) of patients at DL1. CAR-T cells remained detectable in peripheral blood for up to 116 days. Viral copy number in peripheral blood peaked immediately after infusion and decreased to undetectable concentrations within 24 hours.

Additional translational analyses further characterized the in vivo profile of LB2501. No evidence of non-specific transduction was detected in NK cells or other non-T/B/NK lymphocyte populations. Vector integrations were highly polyclonal and diverse. These findings support proof-of-concept for in vivo T-cell engineering, with polyclonal vector integration and rapid vector clearance.

“These early clinical findings are encouraging in a heavily pretreated relapsed or refractory B-cell non-Hodgkin lymphoma population,” said Lei Fan, M.D., Ph.D., Professor, Doctoral Supervisor, and Administrative Director, Hematology Department, Jiangsu Province Hospital, Nanjing, China. “The responses observed at the higher dose level achieved a 100% objective response rate, together with a favorable safety profile and the absence of lymphodepletion, support further investigation of LB2501 as a novel in vivo CAR-T approach. The additional pharmacokinetic and translational findings presented at EHA further support the feasibility of generating CAR-T cells directly within the patient.” ‡

ABOUT LB2501
LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion. It is being evaluated in an ongoing Phase 1, open-label study (NCT07002112) in patients with relapsed/refractory B-cell malignanciesi to assess safety, tolerability, and preliminary efficacy.[i]

ABOUT B-CELL NON-HODGKIN LYMPHOMA
Non-Hodgkin lymphoma (NHL) is a group of cancers that originate in lymphocytes, a type of white blood cell that plays a key role in the body’s immune system.ii B-cell lymphomas account for approximately 85% of NHL cases and arise from abnormal growth of B lymphocytes (B cells), which are responsible for producing antibodies. These malignancies include a range of subtypes that vary in aggressiveness, from slow-growing to highly aggressive disease.iii

While treatment advances have improved outcomes for some patients, those with relapsed or refractory B-cell NHL, particularly after multiple lines of therapy, often face limited options.

ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, the Phase 1 clinical trial of LB2501, and the potential benefits of LB2501, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and LB2501’s potential to be first-in-class. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech’s third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

‡ Lei Fan, M.D., Ph.D., Professor, Doctoral Supervisor, and Administrative Director, Hematology Department, Jiangsu Province Hospital, Nanjing, China, has provided consulting and advisory services to Legend Biotech; he has not been paid for any media work.

INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
[email protected]

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
[email protected]

i ClinicalTrials.Gov. The CD19/ CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/ Refractory B-cell Malignancies. https://clinicaltrials.gov/study/NCT07002112. Accessed May 2026
ii American Cancer Society. “What Is Non-Hodgkin Lymphoma?”. Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html.Accessed May 2026.
iii American Cancer Society. “Types of B-cell Lymphoma.” Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/b-cell-lymphoma.html.Accessed May 2026.

For technology investors, generative artificial intelligence (AI) has been the gift that just keeps giving. Money continues to pour into the sector as Wall Street and Silicon Valley both race to maximize their exposure to what could be a transformational long-term megatrend.

Sandisk (SNDK +5.24%) has been one of this year's biggest winners, with shares up by an eyepopping 600% since January. Let's dig deeper into the pros and cons of the company to decide if it is still a good buy, or if investors should consider taking some profits off the table.

Image source: Getty Images.

What is Sandisk, and why is it booming? While Sandisk is a bit of a household name, it only became publicly available as a stand-alone entity in early February when its parent company, Western Digital, divested ownership. The separation allows each company to focus on its specific niche within the market.

Both companies provide computer memory and storage, but Western Digital specializes in hard disk drives (HDDs), while Sandisk is a leader in solid state drives (SSDs). Unlike HDDs, which use moving parts to store data, SSDs operate with no mechanical components, making them faster, more reliable, and extremely energy-efficient. That last characteristic is crucial for AI data center clients that need to handle massive amounts of information while trying to minimize their costs of operation.

The performance of the two stocks has diverged sharply over the last 12 months. This highlights how SSDs are much better suited to serving the rapidly growing AI infrastructure market.

SNDK data by YCharts.

Business is booming, but what comes next? Sandisk's incredible stock price growth isn't based on hype alone. The company's fiscal third-quarter revenue soared by an eyewatering 251% year over year to $5.95 million, while gross margins rose 55.9 points to 78.4% -- a number higher than many software companies that don't even sell physical products. The combination of soaring growth and margins has caused operating income to explode by 319% to $4.11 billion.

Investors can expect Sandisk's momentum to continue in the near term because generative AI models continue to get larger and more demanding. Furthermore, hyperscalers remain committed to their data center buildouts, with analysts at Goldman Sachs projecting that total capital spending could reach $1.1 trillion in 2027.

Today's Change

(

5.24

%) $

98.59

Current Price

$

1980.10

Furthermore, some industry leaders believe memory shortages could last until 2030. If this is true, producers like Sandisk could continue enjoying the elevated margins by keeping prices high.

That said, the medium- to longer-term situation remains much more difficult to predict. It seems hard to believe that big tech companies will continue to spend sums that often exceed their cash flow on what remains a somewhat speculative technology. It could only be a matter of time before shareholders start pressuring management teams to show more restraint. That could eventually deflate the AI bubble.

Sandisk is also exposed to the cyclicality of the memory industry, which tends to experience booms and busts much like a commodity. Previous surges in memory demand (such as the PC boom in the 1990s or the smartphone boom in the 2010s) ended in sharp crashes as supply caught up to demand and prices cratered. Investors shouldn't expect the current AI-driven boom to change this long-established pattern.

While Sandisk will continue to enjoy elevated revenue and profit growth amid the AI data center boom, this won't last forever, and the risks of a correction are starting to rise. Investors who already own the stock should probably consider taking some profits off the table. Investors who missed the big rally should probably look elsewhere for value.

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Trial lawyer Mark Lanier represented the plaintiffs in the landmark social media addiction trial, where Meta CEO Mark Zuckerberg testified. Wally Skalij/Getty Images One morning in February, Mark Lanier woke up after four hours of sleep and started preparing to cross-examine one of the wealthiest people in the world: Mark Zuckerberg.

His team had worked through the night, preparing material for the day ahead that he could then review in the hours before court, all with the help of AI.

Lanier, a nationally known Texas trial lawyer with a reputation for taking on major corporations in high-stakes trials, was representing the plaintiff in a landmark social media addiction case. He said AI allowed his team to do significantly more with the limited hours they had to prep outside the courtroom during the trial, which lasted over a month.

"It's as if I have 10 additional workers who are incredibly well-trained, who know the file inside and out, who work 24 hours a day and don't even need to take a break for the restroom, much less PTO," he told Business Insider, adding, "In the 10 hours I might be working outside of court, I can get 30 hours of work done."

AI in law has been touted both as a major opportunity and a cautionary tale, with many stories of hallucinations and fake citations. While the legal industry grapples with how to use AI, Lanier said it's been a "total game changer" for him.

Lanier won the case against Meta and Google, in which the jury found the companies negligent and ruled they knew their platforms were "dangerous" but failed to warn the plaintiff, who was awarded $6 million. The case was a bellwether for thousands of similar lawsuits brought against social media companies.

Mark Lanier said using AI has transformed his workflow before and during trial.  Courtesy of Mark Lanier While Lanier had used the most popular AI products, he said the AI tool he relied on before and during the trial was Boodlebox, calling it "Disney World compared to a swing set in the backyard."

A leader in the education technology space, Boodlebox provides access to major models like ChatGPT, Claude, and Gemini, allowing users to switch between them or compare results. It's also collaborative, allowing Lanier and his team of lawyers to work with the AIs in the same digital workspace.

Lanier worked with Boodlebox to create a custom license that costs him six figures annually and is tailored to his needs.

"We could, in essence, take my brain, take 42 years of my experience, take the things that I have learned and studied and published and not published and incorporate it into the brain that drove my AI queries and results," he said.

He relied on AI before and during the landmark trialLanier is careful when talking specifics about how he deploys his AI. He says it's a matter of "trade craft" and that his firm is "doing some things that nobody else is doing."

One example he gave included taking transcripts from court each day and asking different models to evaluate them. He said AI is also great for finding a more creative or visceral way to describe something in court. He even would feed AI jury notes that came up during deliberations and ask it to evaluate where the jury was in the process.

At the end of court each day, they'd meet in his war room, debrief, and assign tasks to everyone, such as pulling the five most critical documents supporting point A. The team would then break and do much of that work in Boodlebox, allowing him to review what they've put together and how. He said he and his team, which includes several of his daughters, spent thousands of hours on the platform.

While most of Boodlebox's clients are big universities, a company representative told Business Insider that the platform is also exploring more enterprise and law adoption, in part because of its work with Lanier.

Lanier said he doesn't use AI in the way that often gets people into trouble. "I'm not going to say, 'Go do my research and write my brief,'" he said, adding that there was one instance in the case where AI cited something from the record and he knew it wasn't correct.

"It's not unbridled," he said. "You are an important part of the equation."

His advice to other lawyers trying to use AI was to keep up with the developments in the rapidly evolving field. He has an AI team at his firm that sends him a document every Friday with all the developments in AI, typically three pages single-spaced.

"Next trial, I will make what I did last trial look like Fred Flintstone and the Stone Age," he said.

Read next

Kelsey Vlamis You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Kelsey is a senior reporter for Business Insider, where she covers business and tech news as well as stories about travel, luxury, and consulting.Her feature story "Disaster at 18,200 feet" received awards from the New York Press Club and the North American Travel Journalists Association, as well as honorable mention from the Society of American Travel Writers. It was also included on Longreads' and Pocket's best of 2022 lists. She has also received an American Journalism Online Award for her coverage on missing and murdered Indigenous people in Wyoming.She's appeared on CBS, NPR, NBC, and other outlets to discuss her work. She previously worked on the world news desk at the BBC in London and received a master's in journalism from Northwestern University.She can be reached by email at [email protected] or via the encrypted-messaging app Signal @kelseyv.21.Popular storiesDisaster on Denali: Inside a 1,000-foot fall on America's highest peakThrifting is more popular than ever. It's also never been worse.Rolex wouldn't service the vintage watch my mom inherited. Watchmakers say it happens all the time.A tiny, invasive bug and the climate crisis are changing how guitars are made, and shifting the course of music historyThe tourism free-for-all is overGovernment-run boarding schools were founded to 'civilize' Native Americans. Hundreds of dead children remain buried in the schoolyard graves.Meet the Texas minister who helps fly dozens of women to New Mexico every month to get abortionsPeople are flocking to Colorado for the great outdoors, but the air pollution is so bad, it's forcing many to stay insideInside Kabul: An aid worker reveals the devastating chaos that erupted during the US exit from Afghanistan

AI Meta Law More

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Microsoft Corporation (“Microsoft” or “the Company”) (NASDAQ: MSFT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between May 1, 2025 and January 28, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 11, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Microsoft’s Copilot AI products suffered from problems ranging from poor user experience to capacity limitations. The Company’s AI model ranked poorly against competitors on industry benchmark tests. The Company would need to spend billions on capital expenditures related to AI including diverting hardware away from profitable business units to improve its competitive posture in artificial intelligence. The Company was incapable of converting a large percentage of Microsoft 365 users to paid Copilot subscriptions, losing market share to rivals. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Microsoft, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260613313708/en/

General Motors said it will roll out eyes-off driving on highways in 2028, starting with the Cadillac Escalade IQ. Tayfun Coskun/Anadolu via Getty Images General Motors may have shut down its dedicated robotaxi division, but it hasn't bowed out of the race.

Sterling Anderson, the former head of Tesla's Autopilot program and GM's chief product officer, told Business Insider in an interview that the company's focus on autonomy in personal cars could be applied to driverless ride-hailing services in the future.

Anderson said GM's approach is to develop self-driving technology by breaking the driving experience into pieces and examining where autonomy is most useful to car owners. That means first tackling long stretches of highway driving before expanding to arterial roads and urban centers.

Over time, the executive said GM's autonomous driving systems will be able to operate in enough regions to make a viable robotaxi service.

"Ultimately, the two converge. Our operating region looks identical to the operating region of a robotaxi company," he said. "The question at that point becomes, 'Why not offer them in a robotaxi-type application as well?'"

GM was once seen as one of the leading challengers to Alphabet's Waymo robotaxis, pouring more than $10 billion into Cruise, the robotaxi startup that it acquired in 2016. The division was shut down in 2024 after facing regulatory hurdles and a safety incident that forced Cruise to pause testing in California.

GM pulled the plug on its robotaxi business, Cruise, in 2024 and has since shifted its resources to personal autonomy.  David Paul Morris/Bloomberg via Getty Images GM has since shifted its focus toward its hands-off, eyes-on driver assistance tech called Super Cruise, akin to Tesla Full Self-Driving. The company said in April that GM customers have driven one billion hands-free miles with the feature and that it plans to introduce eyes-off highway driving in 2028.

The shift has come with a rebuilding of GM's autonomous-driving ranks. Business Insider reported in December that it had hired Ronalee Mann, a former Cruise and Tesla executive, for its renewed self-driving focus inside the company. The Information reported last week that GM has rehired about 100 former Cruise employees to develop eyes-off driving capabilities.

Several other legacy automakers and EV startups are charting their own path to robotaxis. Hyundai-backed Motional launched a robotaxi service with Uber in Las Vegas this year and plans to commercialize fully driverless rides there by the end of 2026. Rivian is also developing autonomous driving for a future robotaxi fleet. The EV maker announced a $1.25 billion robotaxi deal with Uber in March.

While GM isn't jumping headfirst into a robotaxi play, Anderson said the company will be prepared to meet the demand.

"We'll be ready for it," he said. "If that's where the world goes, our autonomous vehicles will be capable of being robotaxis as well."

Have a tip? Contact this reporter via email at [email protected] or Signal at lloydlee.71. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.

Read next

Lloyd Lee You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

GM

Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% with epcoritamab monotherapy in elderly patients with newly diagnosed DLBCL. In the Phase 1b/2 EPCORE NHL-2 study, epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone (R-mini-CHOP) demonstrated an ORR of 93% and a CR rate of 86% in elderly patients with newly diagnosed DLBCL.

The results from both studies were presented in two poster presentations (abstracts PS2082 and PF1007) at the European Hematology Association (EHA) 2026 Congress held in Stockholm, Sweden, June 11-14. Additionally, the full EPCORE DLBCL-3 results have been simultaneously published in The Lancet Haematology.

EPCORE DLBCL-3 Results
The Phase 2 EPCORE DLBCL-3 study (abstract PS2082) evaluated the efficacy and safety of fixed-duration epcoritamab monotherapy in newly diagnosed CD20+ large B-cell lymphoma (LBCL) patients ineligible for anthracycline-based chemotherapy due to age (≥80 years) or comorbidities (≥75 years with comorbidities). Among 66 enrolled patients, the median age was 82.5 years, and all had comorbid conditions (94% with ≥3 comorbidities). With a median follow-up of 21.9 months, epcoritamab monotherapy demonstrated responses in this population with high unmet medical need.

An ORR of 67% and a CR rate of 58% were observed in evaluable patients (n=66). Median time to response was 1.5 months, and median time to CR was 2.2 months. Notably, 11 of 17 patients with a partial response or stable disease at first assessment subsequently achieved a CR.

"For newly diagnosed elderly patients with diffuse large B-cell lymphoma and comorbidities, who are often excluded from standard curative chemotherapy and ineligible for doxorubicin, finding more options is paramount," said Umberto Vitolo, M.D. Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy. "The EPCORE DLBCL-3 study showed that epcoritamab monotherapy offers robust data. Importantly, its safety profile, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, was consistent with expected rates in this fragile population with a high unmet medical need for new therapeutic options."

Responses were durable, with median duration of response (DOR) and duration of complete response (DOCR) not reached. At 12 months, an estimated 67% of responses and 73% of CRs remained ongoing. Median progression-free survival (PFS) was 13.0 months, while median overall survival (OS) was not reached; an estimated 43% of patients remained progression-free and 62% were alive at 18 months. High rates of minimal residual disease (MRD) negativity were observed, with 92% of evaluable responders achieving MRD negativity, typically by Cycle 3 Day 1 and sustained through Cycle 12 Day 1 in most patients.

The safety profile was consistent with expected rates in this elderly population. Cytokine release syndrome (CRS) occurred in 71% of patients, most commonly during Cycle 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 18%. Infections of any grade occurred in 68% of patients (26% Grade ≥3), and neutropenia was reported in 16%, with no febrile neutropenia or clinical tumor lysis syndrome observed. Eight Grade 5 TEAEs occurred.

EPCORE NHL-2, Arm 8 Results
Arm 8 of the Phase 1b/2 EPCORE NHL-2 study (abstract PF1007) evaluated epcoritamab plus R-mini-CHOP in 28 newly diagnosed CD20+ DLBCL patients ineligible for full-dose R-CHOP due to age (≥75 years) or comorbidities (≥65 years with comorbidities). With more than two years of follow-up, fixed-duration epcoritamab plus R-mini-CHOP demonstrated high response rates, sustained MRD negativity and durable remissions.

An ORR of 93% and a CR rate of 86% were observed. Median DOR, DOCR, PFS, and OS were not reached. At two years, estimated DOR and DOCR rates were 79%, while estimated PFS and OS rates were 76% and 82%, respectively.

“The EPCORE NHL-2 Arm 8 results are very encouraging, showing that combining epcoritamab with R-mini-CHOP led to high overall response rates and complete response rates, rapid and sustained minimal residual disease negativity, and durable remissions in this population,” said David Belada, M.D., Department of Internal Medicine—Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic. “These outcomes, alongside a consistent safety profile, potentially support the integration of epcoritamab with standard of care for these vulnerable patients, and highlight its broad utility in combinations across a range of disease settings and patient populations."

Rapid and sustained MRD negativity was observed, with 95% of evaluable patients achieving MRD negativity, including high rates in high-risk subgroups. Outcomes compared favorably with historical results for R-mini-CHOP alone.

The safety profile was consistent with prior reports and the known safety profiles of epcoritamab and R-mini-CHOP. The most common Grade ≥3 treatment-emergent adverse events (TEAEs) were neutropenia (54%), serious infections (33%) and anemia (14%). Most Grade ≥3 serious infections occurred during the first six cycles of treatment with R-mini-CHOP coadministration. TEAEs led to epcoritamab discontinuation in three patients (11%).

“Genmab is committed to evaluating epcoritamab as a potential treatment option in earlier lines of therapy for patients who traditionally struggle with aggressive treatment," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "The robust data observed in both the monotherapy and combination approaches reinforce our vision of making epcoritamab a foundational therapy across the spectrum of B-cell malignancies. These Phase 2 results support our ongoing commitment to addressing the significant unmet medical needs of elderly and comorbid patients, as we seek to identify effective, less intensive and tolerable options."

About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.i,ii DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.iii,iv DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.iv,v

About the EPCORE® DLBCL-3 Trial
EPCORE DLBCL-3 (NCT05660967) is an open-label, randomized, global, Phase 2 trial to evaluate the efficacy and safety of epcoritamab as monotherapy or in combination with lenalidomide as first-line therapy for anthracycline-ineligible subjects with diffuse large B-cell lymphoma (DLBCL). This is a 2-stage trial. In Stage 1, eligible patients were randomized to either epcoritamab monotherapy or epcoritamab plus lenalidomide. In Stage 2, additional patients were enrolled to the epcoritamab monotherapy arm. Each treatment cycle is 28 days. Patients will receive a maximum of 12 cycles (up to 1 year) of treatment. The primary objective is to evaluate the clinical efficacy of epcoritamab monotherapy or epcoritamab and lenalidomide. The primary endpoint is to achieve a complete response rate determined by Lugano criteria. Additional secondary endpoints include overall response rate, duration of response, duration of complete response, rate of minimal residual disease negativity, progression-free survival and overall survival.

More information on this trial can be found at www.clinicaltrials.gov/.

About the EPCORE® NHL-2 Trial
EPCORE NHL-2 (NCT04663347) is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary efficacy endpoint is overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint.

More information on this trial can be found at www.clinicaltrials.gov.

About Epcoritamab
Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.vi

Epcoritamab (approved under the brand name EPKINLY® in the U.S. and Japan, and TEPKINLY® in the EU) has received regulatory approval in certain lymphoma indications in more than 65 territories. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational relapsed or refractory (R/R) follicular lymphoma (FL) indication and additional approvals for the R/R diffuse large B-cell lymphoma (DLBCL) indication.

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes several Phase 3, open-label, randomized trials, including a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658), and a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.

What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:

certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments. follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.

It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:

Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Medication Guide, including Important Warnings.

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.

____________________ i Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed February 2026. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/

ii Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.

iii Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. doi: 10.1056/NEJMra2027612.

iv Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188.

v Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study. Blood. 2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.

vi Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610278575/en/

Obie Mckenzie, Director at Sharplink (SBET +1.47%), reported the direct sale of 12,892 shares for a transaction value of ~$96,000 on May 12, 2026, according to a SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)12,892Transaction value~$96,000Post-transaction shares (direct)24,998Post-transaction value (direct ownership)~$179,000Transaction value based on SEC Form 4 weighted average purchase price ($7.41).

Key questionsHow does this transaction impact Mckenzie’s ownership in Sharplink?
The sale represents a 34.02% reduction in direct holdings, with Mckenzie retaining 24,998 shares directly and no indirect or derivative positions as of May 12, 2026.Was there any indirect or derivative activity associated with this trade?
All shares sold were held directly by Mckenzie; there were no indirect entities involved and no stock options or other derivative securities exercised or disposed.What is the historical context of this sale relative to prior transactions?
This filing marks Mckenzie's second open market sale in nine months, following a direct sale of 18,334 shares in August 2025, suggesting a recurring pattern of trimming director grants back to a consistent floor of roughly 25,000 shares.What does the transaction value signal about the market environment for Sharplink?
The shares were sold at around $7.41 per share, above the post-transaction close of $7.17 on May 12, 2026, during a period when the stock had delivered a 116.6% one-year total return as of the trade date.Company overviewMetricValueRevenue (TTM)$39.4 millionNet income (TTM)($1.4 billion)Price (as of market close June 12, 2026)$5.51* 1-year performance is calculated using June 12, 2026 as the reference date.

Company snapshotSharplink operates an institutional-grade Ethereum treasury platform and provides affiliate marketing services for sportsbook and online casino gaming operators.The company generates revenue through ETH treasury management, including staking and risk-managed custody, as well as performance-based customer acquisition for gaming clients.Primary customers include licensed gaming operators in the U.S. and internationally, as well as institutional clients seeking ETH treasury solutions.Sharplink leverages its dual-segment strategy to address both the digital asset management and gaming affiliate marketing sectors. The company’s ETH treasury management platform is designed for institutional clients, providing staking and governance solutions within a robust risk management framework. Its affiliate marketing network supports gaming operators by driving user acquisition and engagement, positioning Sharplink as a diversified player in digital finance and online gaming services.

What this transaction means for investorsSharplink is essentially a bet on Ethereum. The gaming affiliate business is still there, but the company's identity — and nearly all of its Q1 2026 revenue — now runs through its ETH treasury and staking operations. That pivot is working on the top line: revenue jumped to $12.1 million in Q1 2026 from $0.7 million a year earlier, driven by ETH staking. The bull case is straightforward — Sharplink is accumulating ETH, generating yield on it, and expanding into DeFi through a new Galaxy Digital partnership. If you believe Ethereum has a durable role in institutional finance, the accumulation strategy makes sense. The bear case is just as clear: the company posted a net loss of $685.6 million in Q1, largely from a $506.7 million unrealized loss on crypto assets and a $191.7 million impairment on liquid staking tokens. Those are non-cash GAAP charges, not ETH leaving the treasury, but they signal how much volatility investors are absorbing. McKenzie's sale is a one-paragraph footnote to all of this — a director trimming a comp grant after a strong run. The real question is whether you want ETH exposure through a corporate treasury wrapper, with the added operational and accounting complexity that comes with it, or whether you'd rather own ETH directly. If you're still building your view on the space, check out our article on how to build a crypto portfolio.

Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SpaceX (NASDAQ:SPCX) stock price jumped by 19% on its first day as a publicly-traded company, with its valuation crossing the $2 trillion mark as most analysts were expecting. 

Analysts Have Mixed Opinions on SpaceX StockJim Chanos, the famed short-seller who blew the whistle on Enron, warned that the elevated valuation made no sense. He pointed to its losses and its 2025 revenue of $18 billion.

Why SPCX Stock May Drop After the IPOThere are several reasons why the SpaceX stock will retreat in the coming weeks or months. First, the hype surrounding its IPO will fade as investors embrace the new normal and start focusing on the upcoming OpenAI and Anthropic IPOs. 

Further, the company is losing billions of dollars because of its AI business, which it gained by merging with xAI. Its most recent results showed that it suffered a net loss of over $4.2 billion in the first quarter of this year. It suffered a $4.9 billion last year.

The other reason it may drop is that its tiered lock-up expiry will happen after 180 days. This expiration makes it possible for insiders to start selling their shares. In most cases, stocks often retreat ahead of the expiration date.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

SpaceX has grand ambitions, but it is actually smaller than these two businesses today. Anthropic is seeing huge revenue and profit momentum.

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.

© Ilyas nasrulloh / Shutterstock.com

Passive income arrives while you sleep, commute, or vacation. That appeal drives dividend investing: a paycheck every quarter regardless of market conditions or work hours.

Layoff announcements have rattled white-collar industries through the first half of 2026, and essentials costs climb faster than most household raises. Building a cash-flowing portfolio is one of the few defenses an individual investor controls directly. Unlike rental real estate, a high-yield dividend portfolio is liquid, requires no tenant management, and lets you redirect capital with a single trade.

We screened our 24/7 Wall St. dividend equity research database for stocks that pay massive dividends. A collection of companies can generate over $1,900 a year in passive annual income if you invest $10,000 in each stock at the time of this writing.

Verizon Communications Yield: 6.08% Shares for $10,000: 213 Annual Passive Income: $608 Verizon (NYSE:VZ | VZ Price Prediction) is the largest U.S. wireless carrier and fiber broadband powerhouse following the January 20, 2026 close of the Frontier Communications acquisition, which expanded its fiber footprint to more than 30 million homes and businesses.

The dividend is fueled by predictable subscriber cash flow: FY 2025 operating cash flow of $37.1 billion covered $11.5 billion in common dividends with a 1.75x cushion.

Telecom is a regulated, capital-heavy industry where mature operators return excess cash through dividends rather than reinvest for hypergrowth. Verizon raised its quarterly payout to $0.7075 per share in 2026, extending annual increases spanning over two decades. Management completed $2.5 billion in buybacks in Q1 2026 while paying down Frontier-related debt.

Pfizer Yield: 6.61% Shares for $10,000: 390 Annual Passive Income: $661 Pfizer (NYSE:PFE) is a global biopharmaceutical company spanning Primary Care, Specialty Care, and Oncology, with blockbuster brands including Eliquis, Prevnar, Vyndaqel, Ibrance, Padcev, and Nurtec ODT.

The high yield reflects post-COVID revenue normalization rather than business distress: FY 2025 operating cash flow of $11.7 billion covered $9.8 billion in dividends, and management reaffirmed FY 2026 guidance for adjusted EPS of $2.80 to $3.

Big Pharma pays large dividends because mature drug franchises throw off enormous free cash flow exceeding reinvestment needs. Pfizer has raised the payout for 16 consecutive years, moving the quarterly dividend from $0.32 in 2017 to $0.43 in 2026.

A Vyndamax patent settlement extends U.S. exclusivity to June 2031, and the roughly $7 billion Metsera acquisition plants a stake in the obesity drug market. Institutional ownership sits at 69.4%.

Kraft Heinz Yield: 7.09% Shares for $10,000: 415 Annual Passive Income: $709 Kraft Heinz (NASDAQ:KHC) owns Heinz, Kraft, Philadelphia, Primal Kitchen, Lunchables, and Ore-Ida, selling packaged food across North America, International Developed Markets, and Emerging Markets.

The yield is elevated because the share price has compressed: KHC trades down 29.17% over the past five years as volume softness in coffee, cold cuts, and frozen meals weighed on the multiple.

The dividend has held at $0.40 per quarter since 2019 and is well covered by cash: FY 2025 operating cash flow of $4.46 billion against a $1.9 billion payout works out to 2.35x coverage.

New CEO Steve Cahillane paused the previously announced company split and committed $600 million in incremental marketing and R&D investment. Berkshire Hathaway remains the anchor institutional holder, with insiders owning 27.78% of shares.

The Combined Income Picture Combined, these 3 positions generate $1,978 in annual passive income on a $30,000 investment, a blended yield of 6.59%. Kraft Heinz contributes $709, Pfizer adds $661, and Verizon rounds out the portfolio with $608.

Ticker Investment Yield Annual Income Share of Total KHC $10,000 7.09% $709 35.8% PFE $10,000 6.61% $661 33.4% VZ $10,000 6.08% $608 30.7% Total $30,000 6.59% $1,978 100% Reinvested at the same blended yield, that $1,978 would buy roughly another $130 of annual income next year, then another $138 the year after. Cash flow arriving on a schedule lets a portfolio compound without forcing the investor to time entries, exits, or earnings reactions.

Roper Technologies is a diversified software conglomerate with a 33-year dividend growth streak, now trading below historical valuation averages. ROP's aggressive M&A strategy has driven growth but resulted in rising debt and leverage, now at 3.1x, raising concerns about financial flexibility. Despite strong Q1 2026 results and conservative dividend safety metrics, investor fears of AI disruption and increased private equity competition weigh on sentiment.

CBIZ, Inc. shares have rebounded from 10-year lows after a sharp decline driven by AI disruption fears and increased leverage from acquisitions. With no common dividend, CBZ could potentially repay all debt in about six years using $270-$290 million in annual free cash flow. Unusual underlying value and the prospect of deleveraging have positioned CBZ for a higher equity quote over time.

Coca-Cola (KO +0.11%), the world's largest beverage company, is a reliable blue chip stock. Including reinvested dividends, it delivered a total return of 659% over the past 30 years. Let's see why it's still a great stock to buy today to generate passive income for life.

Why is Coca-Cola an evergreen investment? Over the past few decades, Coca-Cola has expanded its beverage portfolio with more brands of bottled water, fruit juices, teas, sports drinks, energy drinks, dairy products, coffee, and even alcoholic beverages. It also refreshed its flagship sodas with smaller serving sizes, new flavors, and healthier versions. That ongoing expansion and evolution enabled the company to continue growing, even as soda consumption rates fell worldwide.

Image source: Coca-Cola.

Coca-Cola only produces the concentrates and syrups for those beverages, then sells them to independent bottlers, restaurants, and other businesses that produce the finished drinks. That asset-light business model enables it to maintain high operating margins while generating stable cash flow and earnings, even amid economic downturns or choppy macro headwinds. It also doesn't own a struggling packaged foods segment like PepsiCo (PEP +0.35%).

That's also why Coca-Cola raised its dividend annually for 64 consecutive years. That makes it an elite Dividend King, having hiked its payout for at least 50 consecutive years. It currently pays a forward dividend yield of 2.6%. That yield might not seem impressive when the 10-Year Treasury still pays 4.5%, but it will attract more attention as interest rates decline.

Today's Change

(

0.11

%) $

0.09

Current Price

$

82.62

From 2025 to 2028, analysts expect Coca-Cola's EPS to grow at 6.5% CAGR. That growth will be driven by its AI-powered inventory optimization strategies, the ongoing consolidation of its bottling network, as well as its stronger sales of dairy, energy, and sugar-free drinks. Its bottling partners will also continue to sell a higher mix of smaller, higher-margin cans.

Why is Coca-Cola a good stock to buy in June? At $83, Coca-Cola's stock still looks reasonably valued at 25 times its trailing earnings. By comparison, the S&P 500 looks historically expensive at 32 times earnings. Rising inflation, the Middle East conflict, and other macro headwinds could deflate those valuations in the second half of 2026.

If that market pullback happens, more investors will rotate toward safe-haven stocks like Coca-Cola. Therefore, it seems to be a great time to buy more shares of Coca-Cola -- and commit to holding them for decades -- to earn a lifetime of reliable dividends.

Few companies have ever defined a technology shift the way Nvidia (NVDA +0.15%) has defined the rise of artificial intelligence (AI). Its chips sit at the center of nearly every major AI project, and the stock has been one of the market's best performers over the past few years. A run like that keeps one question permanently in the air: at nearly $5 trillion in market value, is there still room for the stock to climb?

There is a great contrast between Nvidia's business momentum and the stock's recent performance. The chipmaker reported another quarter of accelerating growth last month, yet the growth stock sits about 13% below its all-time high and has gone largely sideways for months, even as the broader market climbed.

Is this a buying opportunity?

Image source: Getty Images.

Demand keeps accelerating Nvidia's fiscal first quarter of 2027 (the period ended April 26, 2026) was, by almost any measure, a standout. Revenue rose 85% year over year to $81.6 billion -- faster than the 73% growth of the prior quarter and the 62% before it, an unusual acceleration for a company this large.

Behind that figure is the data center business, where Nvidia's AI chips live. Data center revenue jumped 92% year over year to $75.2 billion, more than 90% of the company's total sales.

And management sounds confident the demand will hold. On the company's fiscal first-quarter earnings call, it pointed to about $1 trillion of revenue from its current Blackwell and next-generation Rubin chips between 2025 and the end of 2027 -- up from about $500 billion a year earlier. Guidance backs this up. Nvidia expects fiscal second-quarter revenue of about $91 billion, and that outlook assumes no data center compute revenue from China.

"Demand has gone parabolic. The reason is simple. Agentic AI has arrived," said Nvidia founder and CEO Jensen Huang during the company's fiscal first-quarter earnings call.

Those sales also carry remarkable margins. Nvidia's gross margin sat near 75% last quarter, and the company returned about $20 billion to shareholders while authorizing another $80 billion in share repurchases. And much of its hardware runs on Nvidia's own software, which developers have spent years building around -- making the company hard to replace even when rivals match its chips.

Today's Change

(

0.15

%) $

0.30

Current Price

$

205.18

What could go wrong But even a great business can turn into a mediocre investment if too much optimism is already baked into the price.

So is Nvidia's valuation reasonable?

Nvidia trades at a price-to-earnings ratio of about 31 -- a premium to the broader market, though hardly extreme for a company growing this fast.

But there are risks that help explain the stock's seemingly conservative valuation.

China is one overhang. The country once made up at least a fifth of Nvidia's data center revenue, and management's outlook now assumes zero revenue from the important market -- a reminder of how quickly geopolitics can close off a major market.

Then there's the awkward fact that some of Nvidia's biggest customers are also its potential rivals. The large cloud providers buying its chips are designing their own at the same time, and if enough of them build future systems without Nvidia's hardware inside, Nvidia's pricing power could weaken over time. And pureplay chip competitors like AMD (AMD +4.91%) are pressing with their own AI accelerators, too.

So, is Nvidia stock a buy?

For investors with a long-term time horizon, I think the stock looks attractive here. The business is exceptional, and the valuation looks attractive relative to the company's recent growth. Still, there are some serious risks. So, keeping any position in the stock small is probably a good idea.

Baidu: AI Stock With A High Safety Margin

1.58K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Past performance is not an indicator of future performance. This post is illustrative and educational and is not a specific offer of products or services or financial advice. Information in this article is not an offer to buy or sell, or a solicitation of any offer to buy or sell the securities mentioned herein. Information presented is believed to be factual and up-to-date, but we do not guarantee its accuracy, and it should not be regarded as a complete analysis of the subjects discussed. Expressions of opinion reflect the judgment of the authors as of the date of publication and are subject to change.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis’ flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

37.44K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of UNIT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Elektros Inc. Continues Advancing Lithium Opportunities, EV Charging Innovation, and Strategic Growth Initiatives

Positioned to Capitalize on Expanding Global Demand for Critical Minerals, Energy Infrastructure, and Electric Vehicles

ELEKTROS INC. (OTC PINK:ELEK)

WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC PINK:ELEK) today provided an update regarding its ongoing focus on hard rock lithium opportunities, patented electric vehicle charging technology, and continued efforts to advance its long-term strategic initiatives in support of the evolving electrification marketplace.

As global demand for electric vehicles, energy storage systems, and critical minerals continues to expand, Elektros remains focused on developing opportunities related to lithium resources and technologies designed to support future transportation and energy infrastructure needs.

"Our vision remains centered on the future of energy, transportation, and critical minerals," stated Shlomo Bleier, Chief Executive Officer of Elektros Inc.

The Company's patented electric vehicle charging technology, protected by U.S. Patent No. 12,522,100, relates to multi-port charging technology designed for electric vehicle charging applications.

As part of its intellectual property strategy, Elektros has communicated with various automotive industry participants regarding its patented technology. The Company recently received correspondence from counsel representing Volkswagen Group of America acknowledging receipt of the Company's patent-related communication and indicating that the matter would be reviewed internally. The correspondence does not constitute an admission of infringement, liability, licensing, or any commercial agreement.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of applicable federal securities laws. Actual results may differ materially from those expressed or implied.

Contact Information
Elektros Inc.
Email: [email protected]
Website: www.elektros.energy

SOURCE: Elektros, Inc.

ELEKTROS INC. (OTC Markets:ELEK)

WEST PALM BEACH, FL / ACCESS Newswire / June 13, 2026 / Elektros Inc. (OTC Markets:ELEK), a publicly traded company focused on electrification opportunities, today provided an update regarding its continued focus on hard rock lithium opportunities, patented electric vehicle charging technology, and strategic initiatives supporting the future of transportation, energy infrastructure, and critical minerals.

As global demand for electric vehicles, battery storage systems, and electrification technologies continues to expand, Elektros remains committed to identifying opportunities associated with lithium resources and technologies that may support long-term growth within the evolving energy marketplace.

"Our vision remains centered on the future of energy, transportation, and critical minerals," stated Shlomo Bleier, Chief Executive Officer of Elektros Inc. "We believe electrification continues to be one of the most significant global trends of our generation, creating opportunities across lithium, energy infrastructure, and advanced transportation technologies."

Lithium continues to play an essential role in modern electric vehicle batteries and energy storage systems. Bloomberg and numerous industry analysts have highlighted lithium's importance in supporting the global transition toward electric transportation and renewable energy infrastructure. Tesla CEO Elon Musk has also publicly emphasized the importance of reliable lithium supplies to support continued electric vehicle production worldwide.

The Company's patented electric vehicle charging technology, protected by U.S. Patent No. 12,522,100, relates to multi-port charging technology designed for electric vehicle charging applications and reflects Elektros' continued focus on innovation.

As part of its intellectual property strategy, Elektros has communicated with various automotive industry participants regarding its patented technology. The Company recently received correspondence from counsel representing Volkswagen Group of America acknowledging receipt of the Company's patent-related communication and indicating the matter would be reviewed internally. Such correspondence does not constitute an admission of infringement, liability, licensing, or any commercial agreement.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Actual results may differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.